跳至主要内容
临床试验/NCT03053141
NCT03053141招募中不适用

RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)

Boston Scientific Corporation8 个研究点 分布在 3 个国家目标入组 100 人开始时间: 2016年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
8
主要终点
Physician Feedback on Software Performance

研究概览

简要总结

The objective of the RHAPSODY study is to evaluate the performance of new software features in subjects undergoing standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Results from this study will be used to guide development and refinement of new software features that may be implemented in future commercial software releases.

详细描述

The Rhythmia Mapping System is designed for electroanatomical mapping in catheter ablation procedures by optimizing the need for speed and accuracy. The system is able to simultaneously acquire data from multiple electrodes. In addition, based on user-defined criteria, the system is able to efficiently acquire data over multiple cardiac beats. When used in conjunction with the Rhythmia Mapping Catheter, the system is able to acquire up to hundreds of points per minute leading to fast and detailed map creation.

Since its market release, physicians and users have gained experience with the Boston Scientific Rhythmia Mapping System in the human clinical setting. Improvements to the first generation system are in development and include new and improved software features and mapping algorithms to enhance the clinical operation. These new and improved software features and algorithms require leveraging clinical use data as part of the development and iteration process.

This study will evaluate the performance of potential next-generation software features in a low-risk clinical environment by streaming raw signals from a commercial Rhythmia Workstation during standard of care cardiac mapping and ablation treatments for tachyarrhythmias, specifically atrial fibrillation, atrial tachycardias, and ventricular tachycardia. The data will be evaluated on a parallel investigational Rhythmia Workstation using prototype software features. These next-generation software features and algorithms will not be available to the physician during the case and will therefore have no diagnostic or therapeutic impact on the clinical case.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 or above, or above legal age and willing and capable of giving informed consent specific to national law
  • Scheduled for standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System.

排除标准

  • Prothrombotic or bleeding tendency due to coagulopathy or blood dyscrasia
  • Inability to tolerate heparin therapy (e.g. heparin induced thrombocytopenia, allergy, etc.)
  • Prosthetic or stenotic valves in the chamber where the intended mapping will occur, or in the path of the catheter access route
  • Active systemic infection or sepsis
  • Hemodynamic instability or shock at baseline precluding ablation in the assessment of the investigator.
  • Presence of intracardiac thrombus, tumor, or other abnormality which precludes catheter introduction
  • Women who are pregnant or lactating
  • Cardiac surgery within the past 90 days
  • Acute myocardial infarction within 3 months
  • Stable/unstable angina or ongoing myocardial ischemia
  • Subjects with an active heart failure decompensation
  • Long QT Syndrome, Brugada Syndrome, or Torsade de Pointes
  • Congenital heart disease with or without corrective surgery that would complicate a mapping procedure
  • Subjects having untreatable allergy to contrast media
  • Vascular pathology or tortuosity precluding standard vascular access techniques
  • Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the patient is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance should be brought to the attention of the sponsor to determine eligibility.

研究组 & 干预措施

All Subjects

All subjects are included in this cohort and are treated with the Rhythmia Mapping System

干预措施: Rhythmia Mapping System (Device)

结局指标

主要结局

Physician Feedback on Software Performance

时间窗: 1 day- Procedure

Physician Feedback on Software Performance

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

RHythmia mAPping and Signal acquisitiOn for Data... | 临床试验